

195 QM

CoP 1809

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Christensen, et al.

Serial No.: 08/612,661

Group No.: 1809

Filed: March 8, 1996

Assistant Commissioner

for Patents

Washington, DC

Examiner: A. Marschel

For: SUBSTITUTED NUCLEIC ACID MIMICS

20231

I, Joseph Lucci, Registration No. 33,307 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On May 5, 1997

Joseph Lucci, Registration No. 33,307

RECEIVED

MAY 23 1997

GROUP 1800

REQUEST FOR RECONSIDERATION

In response to the Office Action mailed December 3, 1996, in connection with the above-captioned patent application, Applicants respectfully request that the following amendments be entered, without prejudice:

In the Specification:

At page 17, line 25, please delete "Phsphoramidates" and insert --Phosphoramidates-- therefor.

In the Claims:

Please cancel claims 9 and 10. Also, please rewrite claim 2 and add claims 11-21 as indicated below:

NO.: ISIS-2169

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Christensen, et al.

Serial No.: 08/612,661 Group No.: 1809

Filed: March 8, 1996

Examiner: A. Marschel

For: SUBSTITUTED NUCLEIC ACID MIMICS

I, Joseph Lucci, Registration No. 33,307 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On May 5, 1997

ation No. 33,307

Assistant Commissioner for Patents Washington DC 20231

Sir:

AMENDMENT TRANSMITTAL LETTER AND REQUEST FOR EXTENSION OF TIME

Transmitted herewith is an amendment in the aboveidentified application.

- Small entity status of this application under 37 (XX) CFR 1.9 and 37 CFR 1.27 has been established by a verified statement previously submitted.
- A verified statement claiming small entity status under 37 CFR 1.9 and 37 CFR 1.27 is enclosed.
- Statement to Support Filing and Submission of (DNA/Amino Acid Sequences in Accordance with 37 CFR §§ 1.821 through 1.825.

The fee for additional claims presented in this amendment has been calculated as follows:

					SMALL ENTITY			OTHER THAN SMALL ENTITY	
	Claims Remaining After Amendment	Highest Number Previously Paid for	No. Extra	Rate	Fee	<u>OR</u>	Rate	Fee	
Total Claims	17	20 (at least 20)	0	x\$11=	\$	<u>OR</u>	x\$22=	\$	
Indep. Claims	1	3 (at least 3)	0	x \$40=	\$	<u>OR</u>	x \$80=	\$	
First Presentation Multiple Dependent Claims +					\$	<u>OR</u>	\$260=	\$	
Total fee for added claims:								\$	

(XX) Request is hereby made under 37 CFR 1.136(a) to extend the time for response to the Office Action of <u>December</u> 3 1996 to and through <u>May 3, 1997</u>, comprising an extension of the shortened period of <u>2 months</u> months:

	SMALL ENTITY		OTHER THAN SMALL ENTITY		
One Month		\$ 55		\$ 110	
Two Months	XX	\$195		\$ 390	
Three Months		\$465		\$ 930	
Four Months		\$735		\$1,470	
Additional fee for	\$195.00				

Applicant(s) has/have not been notified that the requested extension will not be permitted. The present application is not involved in an interference declared pursuant to 37 CFR 1.207.

Total fee required

\$<u>195.00</u>

() Please charge my Deposit Account No. 23-3050 in the amount of \$____. This sheet is attached in triplicate. An extension for $_$ has already been secured and the fee paid therefore of \$ is deducted from the () total fee due for the total months of extension now requested. Extension fee due with this request \$<u>195.00</u> A check in the amount of \$\frac{195.00}{2}\$ is attached. Please (XX) charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. (XX) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in triplicate. (XX) Any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims. (XX) Any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20(d). The Commissioner is hereby authorized to charge payment (XX) of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in triplicate. (XX) Any patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20(d).) The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).

(XX) Any filing fees under 37 CFR 1.16 including fees for presentation of extra claims.

Date: May 5, 1997

Joseph Lucci

(Name of Attorney of Record) Registration No. 33,307

WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 (215) 568-3100